Summit Therapeutics (SMMT) Q3 2026 earnings summary

Executive summary

• Ivonescimab programs span NSCLC, colorectal, urothelial, renal and biliary tract cancers, with additional solid-tumor collaborations.

• AstraZeneca’s $2.0 billion investment closed Oct. 5, supporting accelerated development; Sept. 30 cash, cash equivalents and short-term investments totaled $629.8 million.

• Akeso-reported Phase III studies showed OS benefits in PD-L1-positive NSCLC and biliary tract cancer.

Financial highlights

• Q3 GAAP operating expenses were $214.6 million vs. $234.2 million YoY; R&D was $169.1 million vs. $131.1 million, while G&A was $45.5 million vs. $103.1 million.

• Q3 GAAP net loss was $208.4 million, or $0.26 per share, vs. $231.8 million, or $0.31 per share; non-GAAP net loss was $160.7 million, or $0.20 per share.

• Nine-month GAAP operating expenses were $630.3 million vs. $869.5 million; net loss was $613.5 million, or $0.78 per share, vs. $860.4 million, or $1.16 per share.

Outlook and guidance

• HARMONI’s PDUFA action date was Nov. 14, 2026; a conference call was planned following FDA action.

• HARMONI-3 squamous-cohort primary PFS analysis and early OS interim were expected in Q4 2026; non-squamous PFS events were expected in H1 2027.

• HARMONI-GI3 enrollment was expected to complete in Q3 2027; HARMONI-7 enrollment was expected to complete in 2027.

• Initial Arcus-collaboration data for casdatifan in clear-cell RCC were expected by mid-2027; further global Phase III expansion was planned.

• R&D and G&A expenses were expected to rise as clinical development, infrastructure and headcount expand.